European 100 Study Reveals: Despite Year-over-Year Improvements, Tremendous Opportunity to Enhance Hiring with AI, Automation and Experience Remains
1.6.2023 12:00:00 EEST | Business Wire | Press release
Phenom released the second annual European Edition of its State of Candidate Experience Report, revealing significant improvement in the use of AI over one year and shining a spotlight on enormous opportunities for companies to enhance job seekers’ experiences through intelligence and automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005156/en/
‘State of Candidate Experience: 2023 Benchmarks Report — European Edition’ reveals, despite year-over-year improvements, tremendous opportunity to enhance hiring with AI, automation and experience remains. The second annual report provides recommendations, including small steps for making big impacts. (Photo: Business Wire)
Phenom audited the top 100 European companies of the Global 500 list in three key areas of the talent journey: attraction, engagement and conversion, as well as the use of AI. By viewing their strengths, weaknesses and opportunities for improvement, HR leaders, talent acquisition teams and hiring managers can gain valuable insights and best practices to improve the candidate experience, grow quality talent pools faster and hire more efficiently.
The 2023 audit of European 100 career sites reveals improvement year-over-year to deliver hyper-personalized experiences and job matching that strengthen candidate attraction, engagement and conversion, including a:
- 525% increase in presenting job recommendations based on browsing history
- 67% increase in using a recruitment chatbot
- 64% increase in showing job recommendations based on geographic location
- 60% increase in displaying recently viewed jobs
Although organizations are increasingly adopting AI-powered technology to improve experiences, 94% scored poorly in their use of AI, indicating there is still a significant gap between the solutions available and what companies have implemented. According to the 2023 audit:
- 90% did not use a recruitment chatbot
- 83% did not display recently viewed jobs
- 82% did not share job recommendations based on geographic location
- 75% did not present job recommendations based on browsing history
“Enhancing the candidate experience is a critical step in attracting the right qualified talent in this highly competitive market,” said Mahe Bayireddi, CEO and co-founder of Phenom. “Providing phenomenal, personalized experiences for job seekers is only possible through intelligence and automation.”
The ROI of Intelligence, Automation and Experience
Although retaining employees has become a primary goal for European companies, proactively improving the candidate experience remains an imperative. Organisations are struggling to fill open positions amidst economic challenges including an energy crisis, inflation and an ultra-competitive talent market.
To outpace competitors, employers must embrace cutting-edge practices and AI technology for hiring, developing and retaining talent. Intelligence, automation and experience are essential to overcoming today’s biggest talent acquisition and retention challenges, including simplifying the job search process and maintaining an attractive, unique employer brand. Hyper-personalized career sites, conversational chatbots, automated screening and scheduling, and content that showcases a company’s culture all enrich the candidate experience, helping them find the right job faster and apply.
Savvy organisations that are leveraging AI-powered technology and automation through the Phenom Intelligent Talent Experience platform are attracting more best-fit job seekers, growing talent communities and increasing completed applications, and the results speak for themselves:
- A major telecommunications company increased career site traffic by 220% and increased completed applications by 700% with intelligent tools that provided a more personalized experience for candidates
- A large health care organisation achieved a 10% increase in nursing hires by expediting communication with candidates through a conversational chatbot and SMS messages
- A leading financial institution added 8X more candidates to their talent community by creating a dynamic, hyper-personalized career site and targeting recruitment marketing efforts
- A popular restaurant chain registered over 12,000 candidates through their career site and talent email campaigns in less than a month — resulting in more than 2,000 same-day offers to candidates and 1,300+ same-week hires
Actions Organisations Can Take to Accelerate Hiring
To improve the candidate experience, Phenom’s European Edition of its State of Candidate Experience Report prescribes a series of actions organisations can take — from creating strong employer brand content to implementing intelligent technology on its career site:
- Personalize the candidate experience through AI and automation. Candidates today expect the online job search to be similar to purchasing consumer goods, where relevant information is delivered based on their interests. If this process isn’t intuitive and simple, they are more likely to drop off a career site. With AI and automation on a career site, personalized jobs and content automatically displayed for candidates based on their resume, experience, skills, and geographic location.
- Showcase a strong employer brand through content. When deciding if a job is the right fit for them, candidates spend a significant amount of time researching a company. If your digital brand doesn’t meet their expectations, they may not feel a strong connection and apply to an open role. Content on a career site (videos, pictures, blogs, etc.) that conveys information such as your company’s mission and purpose, overall workplace culture, employee quotes and stories, internal events and employee resource groups all paint a picture of what it’s like to work there.
- Embrace cutting-edge technology. In addition to AI and automation, organizations must be quick to adopt work-altering innovations, such as: generative AI — which enables organisations to reach previously unattainable levels of productivity and fill roles faster by automatically creating content, surfacing actionable intelligence, and eliminating time-consuming tasks; interview intelligence, which brings transparency to hiring teams through recordings, transcriptions, key takeaway, and analysis to move the process forward faster; and candidate hub, a one-stop-shop that helps candidates understand where they are in the hiring process and prepare for next steps.
With Phenom, candidates find and choose the right job faster, employees develop their skills and evolve, recruiters become wildly productive, managers build stronger-performing teams, HR aligns employee development with company goals, and HRIS easily integrates existing HR tech to create a holistic infrastructure.
To read the full State of Candidate Experience: 2023 Benchmarks Report — European Edition and company rankings, download here.
About Phenom
Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, employers are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, hiring managers, HR and HRIS — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (3 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230601005156/en/
Contact information
Media:
Jennifer Lyons
Director, Global Communications
267-379-5066
jennifer.lyons@phenompeople.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
